Eko Health Appoints Dr. Steven Steinhubl as CMO to Drive Cardiac AI and Global Clinical Strategy

Why It Matters

Steinhubl’s expertise bridges clinical evidence and commercial scaling, positioning Eko to accelerate revenue growth and solidify its leadership in AI‑driven cardiology, a market projected to exceed $10 billion.

Key Takeaways

• Dr. Steven Steinhubl joins Eko Health as Chief Medical Officer
• Eko's AI stethoscope platform sold over 700,000 devices worldwide
• CMS reimburses Eko's SENSORA® at $128.90 per use
• Lancet TRICORDER study shows AI improves heart failure detection 2.3x
• Expansion into UK and Canada broadens global patient reach

Pulse Analysis

Cardiovascular disease remains the leading cause of death worldwide, and early detection is a persistent clinical bottleneck. Eko Health has positioned itself at the intersection of digital health and cardiology by embedding artificial intelligence into the everyday tools of clinicians—a digital stethoscope and a single‑lead ECG. Its FDA‑cleared SENSORA® platform, now deployed in more than 700,000 devices, converts acoustic and electrical signals into actionable analytics without disrupting workflow. The technology’s ability to flag heart failure, atrial fibrillation and lung pathology in real time has attracted both providers and payers, setting the stage for broader adoption.

To accelerate that adoption, Eko announced the appointment of Dr. Steven R. Steinhubl as chief medical officer. A professor of biomedical engineering at Purdue and a veteran of wearable‑based health research, Steinhubl has authored more than 150 peer‑reviewed papers and co‑founded several digital‑medicine startups. His work on the Apple Watch ECG and on AI‑driven remote monitoring has demonstrated measurable reductions in hospital readmissions and improved equity in underserved populations. At Eko, he will steer clinical trial design, expand scientific collaborations, and translate the TRICORDER study’s 2.3‑fold heart‑failure detection gain into real‑world practice.

The timing of Steinhubl’s hire aligns with two market catalysts. In July 2025, the Centers for Medicare & Medicaid Services granted national payment for Eko’s SENSORA® platform at $128.90 per use, providing a predictable revenue stream and encouraging provider uptake. Meanwhile, regulatory clearances in the United Kingdom and Canada have opened new payer ecosystems, expanding the company’s addressable base beyond the 1.5 million patients already served. Analysts expect that the combination of robust clinical evidence, reimbursement certainty, and Steinhubl’s leadership will accelerate Eko’s path toward a multi‑billion‑dollar valuation in the burgeoning AI‑cardiology space.